Genelabs Technologies Inc., of Redwood City, Calif., was issued U.S. Patent No. 7,045,513, titled "DHEA Compositions and Method," which claims pharmaceutical formulations of dehydroepiandrosterone in certain purified polymorphic forms. DHEA is the active ingredient in Prestara, the company's lupus drug.

Gene Logic Inc., of Gaithersburg, Md., was granted U.S. Patent No. 7,020,561, titled "Methods and Systems for Efficient Comparison, Identification, Processing and Importing Gene Expression Data," which covers several aspects of its Genesis Enterprise System software for storing, managing and analyzing large amounts of gene expression data.

Genesis Bioventures Inc., of New York, was granted a patent for the Rapid Prion Detection Assay technology developed by Prion Developmental Laboratories, a portfolio company of GBI.

Iomai Corp., of Gaithersburg, Md., received U.S. Patent No. 7,037,499, titled "Adjuvant for transcutaneous immunization," which outlines methods for inducing an immune response to the company's skin-patch-based vaccines.

MatTek Corp., of Ashland, Mass., received a patent covering its EpiVaginal product, a human cell-derived tissue model that incorporates immune cells for use by HIV/AIDS researchers investigating HIV infection in women.

Monogram Biosciences Inc., of South San Francisco, received notices of allowance for patents related to the use of its phenotypic technology for assessing the efficacy of HIV entry inhibitors. The technology enables the identification of co-receptor usage by HIV.